Beyond The Straight Line: Rethinking How We Forecast Clinical Trial Timelines

By Jeffrey Zimmerman, senior director, data science, PPD™ clinical research business of Thermo Fisher Scientific

As machine learning reshapes clinical operations, traditional enrollment forecasting models are becoming increasingly inadequate. This piece explores how fixed-rate projections, long embedded in executive reporting structures, feasibility plans, and stakeholder communications, fail to capture the dynamic realities of modern clinical trials. By leveraging ML-driven forecasting models that continuously ingest real-time operational, regional, and site-level data, sponsors can move toward adaptive milestone projections that better reflect actual trial performance.

This article examines how explainable AI, probability-based reporting, and hybrid forecasting approaches can improve transparency while supporting executive decision-making. It also addresses the organizational and cultural shifts required to modernize reporting structures built around static enrollment assumptions. Ultimately, the piece positions dynamic ML forecasting as a critical evolution for improving predictability, operational agility, and confidence in clinical trial timeline reporting.